If true (about all nine), that would matter because the early efficacy signals could mostly reflect combination activity, not FT836 monotherapy, so it becomes harder to infer whether FT836 alone contributes meaningfully.
As for LD chemo and RT, true, but the current protocol has a number of arms, including with paclitaxel, which suggests they think tumour/TME preparation may matter.
Also, the HER2 arms may exist because of different populations and a broader commercial opportunity.
Market Data 
Markets 
AI
